Syncom Formulation (India)BOM:524470 +1.21%86 Median PS Value is ₹10.68 as of Jul. 11, 2026, which is 100% below its 10-year median of 2.13. GuruFocus rates BOM:524470 with a GF Score™ of 86/100 and a GF Value™ of ₹19.93 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 544 Drug Manufacturers companies, Syncom Formulation (India) ranks worse than 75.92% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Syncom Formulation (India)'s Median PS Value or its related term are showing as below:
BOM:524470'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.96 Med: 2.13 Max: 3.26
Current: 1.33
During the past 13 years, the highest Price to Median PS Value of Syncom Formulation (India) was 3.26. The lowest was 0.96. And the median was 2.13.
BOM:524470's Price-to-Median-PS-Value is ranked worse than 75.92% of 544
companies
in the Drug Manufacturers industry
Industry Median: 0.86
vs BOM:524470: 1.33
Syncom Formulation (India) (BOM:524470) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Syncom Formulation (India)'s Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
14.18
/
10.68
=
1.33
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Syncom Formulation (India) Median PS Value Related Terms
Syncom Formulation (India) Median PS Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:524470 vs ZTS, UTHR: Median PS Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Syncom Formulation (India)'s Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Syncom Formulation (India) Price-to-Median-PS-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Syncom Formulation (India)'s Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Syncom Formulation (India)'s Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 1.8635.
Syncom Formulation (India)'s Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹5.731.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Syncom Formulation (India) (BOM:524470) has a Median PS Value of ₹10.68 as of Jul. 11, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Syncom Formulation (India) and its competitors. This is 401% above median its historical median of 2.13. Over the past decade, Syncom Formulation (India)'s Median PS Value has ranged from 0.96 to 3.26. According to the industry distribution chart, Syncom Formulation (India) ranks #413 out of 544 companies in the Drug Manufacturers industry, placing it in the top 75.9%.
Is Syncom Formulation (India)'s Median PS Value too high?
Syncom Formulation (India)'s current Median PS Value of ₹10.68 is 401% above median its 10-year median of 2.13. Over the past 10 years, this metric has ranged from a low of 0.96 to a high of 3.26. Based on the distribution chart, Syncom Formulation (India) ranks #413 out of 544 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Syncom Formulation (India) has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Syncom Formulation (India)'s Median PS Value compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Syncom Formulation (India) ranks #413 out of 544 companies for Median PS Value. This places Syncom Formulation (India) in the lower half of its industry. The industry median Median PS Value is 0.86. Historically, Syncom Formulation (India)'s own Median PS Value has ranged from 0.96 to 3.26 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Drug Manufacturers company?
The median Median PS Value among Drug Manufacturers companies is 0.86, based on 544 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Syncom Formulation (India) and its competitors. For the Drug Manufacturers industry, the median Median PS Value is 0.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Syncom Formulation (India)'s current Median PS Value is ₹10.68, which is 401% above median its own 10-year median of 2.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syncom Formulation (India) stock overvalued right now?
Based on GuruFocus' analysis, Syncom Formulation (India) (BOM:524470) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹19.93, compared to a current price of ₹14.18 — trading 28.9% below its estimated fair value. The current Median PS Value is ₹10.68, which is 401% above median its 10-year median of 2.13. Syncom Formulation (India)'s overall GF Score™ is 86/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Syncom Formulation (India) (BOM:524470), the current Median PS Value is ₹10.68 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Syncom Formulation (India) (BOM:524470) Overvalued in 2026?
Based on GuruFocus' analysis, Syncom Formulation (India) stock appears to be undervalued.
The current stock price of ₹14.18 is trading 28.9% below its estimated GF Value™ of ₹19.93.
GuruFocus considers Syncom Formulation (India) to be Modestly Undervalued.
Key valuation signals for BOM:524470:
Median PS Value: ₹10.68 (401% above median its 10-year median of 2.13)
GF Value™: ₹19.93 vs. price of ₹14.18 (28.9% below fair value)
No single metric tells the full story. See the BOM:524470 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Syncom Formulation (India) Ltd is in the business of pharmaceuticals. The company operates through three segments including manufacturing and dealings in Pharmaceutical drugs and formulations, Trading of commodities, and Renting of property. It manufactures and markets pharmaceutical formulation products in various dosage forms like tablets, capsules, liquids orals, liquids vials, ampoule injections and dry vial injections, dry syrups, ointments, inhalers, and Herbals. The company's product includes generic, antiviral, antidepressant, cough suppressant, electrolyte, histamine, estrogen, and much more. It generates maximum revenue through the Pharmaceutical drugs and formulations segment.
86GF Score
Get the complete analysis for BOM:524470
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524470 has been successfully added to your 
